Abstract Library

#754 Effect of Dacarbazine Chemotherapy in Well-Differentiated Neuroendocrine Tumors

Introduction: Streptozocin-based chemotherapies are widely used in pancreatic NEN. Dacarbazine (DTIC) (650mg/m2 every four weeks) can easily be applied in an outpatient setting, but data on efficacy are limited.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Mueller D, Krug S, Majumder M, Gress T, Rinke A,

Keywords: NEN, DTIC, MGMT,

#101 Chronic Complications of Peptide Receptor Radionuclide Therapy (PRRT)- A Single Center Experience

Introduction: In the last decade, a new treatment modality, peptide receptor radionuclide therapy (PPRT), has been introduced for gastroenteropancreatic neuroendocrine tumor (GEPNET) patients with non-resectable or progressive disease. PRRT has been associated with several complications, including bone marrow suppression, renal toxicity and hepatic damage.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Fraenkel M, Barak D, Mueller-Brand J, Krausz Y, Glaser B,

Keywords: PRRT, chronic complications, GEPNET,

#21 Peptide Receptor Radioligand Therapy (PRRT) is an Effective Treatment for the Long-Term Stabilization of Malignant Gastrinomas

Introduction: Gastrinomas represent a rare group of neuroendocrine tumors usually located in the duodenum or pancreas. They secrete gastrin, which is responsible for the clinical picture of severe acid-related peptic disease and diarrhea, known as the Zollinger-Ellison syndrome (ZES). While symptomatic control may be achieved with proton-pump inhibitors (PPIs) and somatostatin analogues (SSAs) treatment, little data is known regarding the possible anti-tumor effect of the peptide receptor radioligand therapy (PRRT) in gastrinoma patients.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Grozinsky-Glasberg S, Barak D, Fraenkel M, Müeller J, Shimon I,

Keywords: PRRT, malignant gastrinoma, treatment, anti-tumor effect ,